Allspring Global Investments Holdings LLC Has $3.08 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Allspring Global Investments Holdings LLC boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 83.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,822 shares of the specialty pharmaceutical company's stock after purchasing an additional 36,331 shares during the period. Allspring Global Investments Holdings LLC owned about 0.24% of Collegium Pharmaceutical worth $3,084,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Gladius Capital Management LP purchased a new stake in shares of Collegium Pharmaceutical in the second quarter valued at $32,000. nVerses Capital LLC lifted its holdings in Collegium Pharmaceutical by 1,600.0% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,600 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock worth $55,000 after purchasing an additional 792 shares during the last quarter. CWM LLC boosted its stake in shares of Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after purchasing an additional 736 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $204,000.

Analyst Ratings Changes

Several analysts have commented on the company. Piper Sandler restated a "neutral" rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Truist Financial upped their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Needham & Company LLC reiterated a "hold" rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, October 23rd. Finally, HC Wainwright increased their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research report on Thursday, September 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus target price of $42.60.

Collegium Pharmaceutical Stock Down 1.6 %

NASDAQ COLL traded down $0.57 during trading hours on Wednesday, reaching $34.67. 180,746 shares of the company traded hands, compared to its average volume of 440,081. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical, Inc. has a 12 month low of $21.40 and a 12 month high of $42.29. The company has a 50 day moving average of $37.62 and a two-hundred day moving average of $35.29. The stock has a market capitalization of $1.13 billion, a PE ratio of 14.68 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. The firm had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.13 EPS. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.79 earnings per share for the current year.

Insider Activity

In related news, EVP Thomas B. Smith sold 9,593 shares of the firm's stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares of the company's stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the business's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company's stock, valued at $1,970,741.92. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the company's stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now owns 120,161 shares in the company, valued at approximately $4,602,166.30. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.